{"id":"ilaprazole-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ilaprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This reduces intragastric acidity and allows healing of acid-related lesions. It is a benzimidazole-based PPI with a rapid onset and extended duration of action.","oneSentence":"Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:37.109Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric ulcer"},{"name":"Duodenal ulcer"},{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Zollinger-Ellison syndrome"}]},"trialDetails":[{"nctId":"NCT06284876","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-07-23","conditions":"Peptic Ulcer","enrollment":416},{"nctId":"NCT03342456","phase":"PHASE4","title":"The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2017-12-13","conditions":"Duodenal Ulcer Due to Helicobacter Pylori","enrollment":184},{"nctId":"NCT03444883","phase":"PHASE3","title":"Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2018-10-31","conditions":"Non-erosive Reflux Disease","enrollment":277},{"nctId":"NCT02638584","phase":"PHASE4","title":"Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-12","conditions":"Gastric Cancer","enrollment":176},{"nctId":"NCT03362281","phase":"PHASE3","title":"Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-10","conditions":"Peptic Ulcer Hemorrhage","enrollment":540},{"nctId":"NCT03362268","phase":"PHASE2","title":"IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-02","conditions":"Peptic Ulcer Hemorrhage","enrollment":180},{"nctId":"NCT02860624","phase":"PHASE3","title":"Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2011-12","conditions":"Gastroesophageal Reflux Disease","enrollment":550},{"nctId":"NCT02847455","phase":"PHASE2, PHASE3","title":"Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2008-08","conditions":"Duodenal Ulcer","enrollment":408},{"nctId":"NCT02401477","phase":"PHASE4","title":"Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2014-12","conditions":"Helicobacter Infections","enrollment":90},{"nctId":"NCT02352701","phase":"","title":"Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2012-12","conditions":"Helicobacter Infections","enrollment":320},{"nctId":"NCT01107938","phase":"PHASE2","title":"Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2010-05","conditions":"Gastroesophageal Reflux Disease","enrollment":330},{"nctId":"NCT00953381","phase":"PHASE2","title":"Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2004-10","conditions":"Duodenal Ulcer","enrollment":235},{"nctId":"NCT00952978","phase":"PHASE3","title":"Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2005-09","conditions":"Duodenal Ulcer","enrollment":496}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ilaprazole Placebo-matching tablet"],"phase":"phase_3","status":"active","brandName":"Ilaprazole tablet","genericName":"Ilaprazole tablet","companyName":"Livzon Pharmaceutical Group Inc.","companyId":"livzon-pharmaceutical-group-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastric ulcer, Duodenal ulcer, Gastroesophageal reflux disease (GERD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}